Psychedelic Innovation: New Orleans Spotlight
Join Nucleate New Orleans, New Orleans BioInnovation Center, and 2A Biosciences on Thursday, February 26th for a networking and panel session on psychedelic innovation in New Orleans!
Enjoy complementary food and beverages, connect with individuals interested in innovation, neuroscience, and related fields, and engage with our incredible panelists as we discuss the current and future of psychedelic and serotonergic innovation.
Spots are limited. RSVP to secure your spot!
Panelists include Dave Weiner (Tulane Innovation), Dr. Charles Nichols (LSU Health Sciences Center), Josh Hardman (Psychedelic Alpha), and Alex Speiser (2A Biosciences). The event with be moderated by Taylor Marcus (Nucleate New Orleans).
We can't wait to see you there!
About the Hosts:
Nucleate is a 501(c)(3) nonprofit organization dedicated to empowering the next generation of biotech leaders. With chapters spanning 41 geographic regions and participation from over 280 academic institutions, Nucleate sparks new intellectual communities and embeds emerging talent within a global biotech community. Through open-access educational programming, Nucleate helps democratize biotech innovation — removing barriers and helping founders concentrate on building transformational technologies. Visit www.nucleate.org for more information, and visit https://nucleate.org/privacy-policy/ to read our privacy policy.
Nucleate New Orleans is sponsored by the New Orleans BioInnovation Center, the Tulane Freeman School of Business Albert Lepage Center, The Idea Village, the Tulane Innovation Institute, PlansConnect LLC, and The Shop Coworking.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
The New Orleans BioInnovation Center is a private, not-for-profit business incubator, supporting entrepreneurship and dedicated to the development of bioscience innovation throughout Louisiana. The Center works directly with entrepreneurs and researchers to commercialize new technologies spinning out of Louisiana universities and healthcare institutions, as well as those developed by independent innovators, to start and scale new globally competitive life science companies.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
2A Biosciences develops next-generation psychedelic-inspired small molecules designed to deliver the therapeutic biology of psychedelics without behavioral effects or safety liabilities. They are launching with a topical eye drop for neurodegenerative eye disease, using vision as an initial entry point into a broader longevity-oriented platform.